美國子宮內膜異位症治療市場規模、佔有率、趨勢分析報告，按治療類型、藥物類別、給藥途徑、分銷管道、細分預測，2025-2030 年

美國子宮內膜異位症治療市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，美國子宮內膜異位症治療市場規模預計到2030年將達到12.841億美元，2025年至2030年期間的複合年成長率為11.86%。

子宮內膜異位症的特徵是子宮外存在類似子宮內膜的組織，越來越被認為是嚴重的健康問題。據約翰霍普金斯醫學院稱，這種疾病影響了美國25至40歲女性的2％至10％，給患者帶來身體、精神和經濟負擔，常常降低他們的生活品質並限制他們參與日常生活。

子宮內膜異位症的盛行率不斷上升，推動了對創新治療方法的需求，以滿足未滿足的醫療需求。製藥公司正積極開發標靶治療，以改善子宮內膜異位症患者的治療效果。例如，輝瑞和 Myovant Sciences 於 2022 年 8 月實現了一個重要里程碑，FDA核准了Myfenvry，這是一種旨在治療閉經女性中度至重度疼痛的新型口服療法。此項核准體現了該行業致力於解決子宮內膜異位症患者面臨的獨特挑戰。

強調早期診斷和及時治療的公眾意識宣傳活動也對市場成長做出了重大貢獻。紐約州衛生部每年舉辦的子宮內膜異位症宣傳月等活動，以及子宮內膜異位症基金會等組織的宣傳活動，旨在教育公眾並減少人們對這種疾病的恥辱感。這些宣傳活動強調了慢性疼痛、不孕症和精神健康問題等疾病的嚴重影響，並鼓勵患者尋求有效的治療。

研發方面的投資正在加速市場擴張。政府、私人公司和製藥公司正在投入大量資源來推動子宮內膜異位症的治療。值得注意的例子包括 Sunstone Life Science Ventures，該公司於 2019 年向 Forendo Pharma 投資 559 萬美元，用於開發新型治療方法，以及 AIMA Laboratories，該公司於 2022 年融資 4.685 億美元，用於創新用於資金籌措子宮內膜異位症的居家血液檢測技術。這些努力凸顯了尖端治療和診斷進步所推動的市場成長潛力。

儘管取得了進展，但市場仍面臨挑戰。非處方藥（OTC）和學名藥的盛行正在抑製品牌藥的成長。注重成本的患者通常會選擇非處方藥，例如學名藥和非類固醇抗發炎藥（例如阿斯匹靈、萘普生、Ibuprofen），來控制子宮內膜異位症相關的疼痛和發炎。這些方便且價格合理的替代療法通常用於治療較輕微的症狀，這限制了更先進的荷爾蒙療法和外科手術的可用性。

總體而言，由於人們對該疾病的認知不斷提高、治療方案的創新和研發投入的加大，子宮內膜異位症市場正處於關鍵的十字路口。儘管定價問題和學名藥競爭仍然是挑戰，但市場趨勢為相關人員提供了解決未滿足需求和改善病患生活的重要機會。

美國子宮內膜異位症治療市場亮點

• 根據治療類型，荷爾蒙療法領域將在 2024 年佔據市場最大收入佔有率，達到 78.51%。荷爾蒙療法是治療子宮內膜異位症症狀（尤其是疼痛和發炎）最有效、應用最廣泛的治療方法，在市場上佔據主導地位。
• 依藥物類別分類，促性腺激素分泌釋放激素 (GnRH) 療法佔據市場主導地位，2024 年銷售額佔有率最大，為 51.33%。 GnRH 療法因其針對性的作用機制，可以抑制子宮內膜生長，具有良好的療效和依從性，因而受到高度青睞。
• 根據給藥途徑，口服藥物佔市場主導地位，2024 年銷售額佔有率最大，為 49.14%。口服給藥因其方便、易用和患者依從性而成為子宮內膜異位症治療的主要方式。
• 依分銷通路分類，零售藥局部門佔據市場主導地位，2024 年銷售額佔有率最大，為 60.99%。零售藥局因其廣泛的可及性和在配發處方箋藥方面發揮的作用而成為主要的分銷管道，尤其是針對子宮內膜異位症等慢性病的處方藥。

目錄

第 1 章美國子宮內膜異位症治療市場：調查方法與範圍

第 2 章美國子宮內膜異位症治療市場：執行摘要

• 美國子宮內膜異位症治療市場：市場展望
• 美國子宮內膜異位症治療市場：市場區隔
• 美國子宮內膜異位症治療市場：競爭考察

第3章美國子宮內膜異位症治療市場：產業展望

• 美國子宮內膜異位症治療市場的系統展望
• 使用者觀點分析
• 滲透和成長前景規劃
• 監管和報銷框架
• 市場動態
• 美國子宮內膜異位症治療市場分析工具
• 美國子宮內膜異位症治療市場管道分析
• 美國子宮內膜異位症治療市場未滿足需求分析

第 4 章美國子宮內膜異位症治療市場：競爭格局

• 主要市場參與企業的近期趨勢和影響分析
• 公司分類
• 供應商概況
• 上市公司
• 私人公司

第 5 章美國子宮內膜異位症治療市場：治療類型的商業分析

• 美國子宮內膜異位症治療市場：治療類型變化分析

第6章美國子宮內膜異位症治療市場：給藥途徑業務分析

• 美國子宮內膜異位症治療市場：給藥途徑變化分析

第7章美國子宮內膜異位症治療市場：藥物類別商業分析

• 美國子宮內膜異位症治療市場：藥物類別變化分析

第 8 章美國子宮內膜異位症治療市場：通路業務分析

• 美國子宮內膜異位症治療市場：通路變化分析

第9章美國子宮內膜異位症治療市場：公司概況

• 公司簡介

U.S. Endometriosis Treatment Market Growth & Trends:

The U.S. endometriosis treatment market size is anticipated to reach USD 1,284.10 million by 2030 and is projected to grow at a CAGR of 11.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. Endometriosis, characterized by the presence of tissue similar to the uterine lining outside the uterus, is increasingly recognized as a critical health concern. Affecting 2% to 10% of women aged 25 to 40 in the United States, according to Johns Hopkins Medicine, the condition imposes significant physical, emotional, and economic burdens on patients, often reducing their quality of life and limiting their participation in daily activities.

The growing prevalence of endometriosis has catalyzed demand for innovative treatments that address unmet medical needs. Pharmaceutical companies are actively developing targeted therapies to improve outcomes for affected individuals. For example, Pfizer Inc. and Myovant Sciences achieved a key milestone with the FDA approval of MYFEMBREE in August 2022, a novel oral therapy designed to treat moderate to severe pain in premenopausal women. This approval reflects the industry's commitment to addressing the specific challenges of endometriosis patients.

Public awareness campaigns also contribute significantly to market growth by emphasizing early diagnosis and timely treatment. Initiatives such as Endometriosis Awareness Month, observed annually by the New York State Department of Health, and advocacy efforts by organizations like the Endometriosis Foundation aim to educate the public and reduce stigma surrounding the condition. These campaigns underscore the severe impact of symptoms such as chronic pain, infertility, and mental health issues, encouraging patients to seek effective care.

Investments in research and development (R&D) are accelerating market expansion. Governments, private organizations, and pharmaceutical companies are dedicating significant resources to advancing endometriosis treatment. Noteworthy examples include Sunstone Life Science Ventures' USD 5.59 million investment in Forendo Pharma in 2019 for developing novel therapies, and AIMA Laboratories' USD 468.5 million funding in 2022 to innovate at-home blood-testing technologies for endometriosis diagnosis. These efforts highlight the market's potential for growth through cutting-edge therapeutic and diagnostic advancements.

Despite this progress, the market faces challenges. The widespread availability of over-the-counter (OTC) and generic drugs poses a restraint on the growth of branded pharmaceuticals. Cost-conscious patients often turn to generic medications or OTC options such as NSAIDs (e.g., aspirin, naproxen, ibuprofen) for managing pain and inflammation associated with endometriosis. These accessible and affordable alternatives are commonly chosen for mild symptoms, limiting the uptake of more advanced hormonal or surgical interventions.

Overall, the market stands at a pivotal juncture, driven by increasing disease awareness, innovation in therapeutic solutions, and robust R&D investments. While affordability concerns and competition from generics remain challenges, the market's trajectory indicates significant opportunities for stakeholders to address unmet needs and improve the lives of patients.

U.S. Endometriosis Treatment Market Highlights

• Based on treatment type, the hormone therapy segment led the market with the largest revenue share of 78.51% in 2024. Hormone therapy is the most effective and widely prescribed treatment for managing endometriosis symptoms, particularly pain and inflammation, driving its dominance in the market.
• Based on drug class, the gonadotropin-releasing hormone (GnRH) therapies segment led the market with the largest revenue share of 51.33% in 2024. GnRH therapies are highly preferred due to their targeted mechanism of action in suppressing endometrial growth, offering significant efficacy and compliance.
• Based on route of administration, the oral segment led the market with the largest revenue share of 49.14% in 2024. The oral route is favored for its convenience, ease of use, and patient adherence, making it the leading segment for endometriosis treatments.
• Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 60.99% in 2024. Retail pharmacies are the primary distribution channel due to their widespread accessibility and role in dispensing prescription medications, especially for chronic conditions like endometriosis.

Table of Contents

Chapter 1 U.S. Endometriosis Treatment Market: Methodology And Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates And Forecast Timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.6.2 Volume Price Analysis (Model 2)
    • 1.6.2.1 Approach 2: Volume Price Analysis
    • 1.6.2.2 Revenue Modeling
• 1.7 List Of Secondary Sources
• 1.8 List Of Primary Sources

Chapter 2 U.S. Endometriosis Treatment Market: Executive Summary

• 2.1 U.S. Endometriosis Treatment Market: Market Outlook
  • 2.1.1 Market Summary
• 2.2 U.S. Endometriosis Treatment Market: Market Segmentation
• 2.3 U.S. Endometriosis Treatment Market: Competitive Insights

Chapter 3 U.S. Endometriosis Treatment Market: Industry Outlook

• 3.1 U.S. Endometriosis Treatment Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 User Perspective Analysis
• 3.3 Penetration & Growth Prospect Mapping
• 3.4 Regulatory And Reimbursement Framework
• 3.5 Market Dynamics
  • 3.5.1 Market Driver Analysis
  • 3.5.2 Market Restraint Analysis
• 3.6 U.S. Endometriosis Treatment Market Analysis Tools
  • 3.6.1 Porter's Five Forces Analysis
  • 3.6.2 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.3 Major Deals & Strategic Alliances Analysis
    • 3.6.3.1 New Product Launch
    • 3.6.3.2 Mergers And Acquisitions
    • 3.6.3.3 Expansion
    • 3.6.3.4 Partnerships
    • 3.6.3.5 Market Entry Strategies
• 3.7 U.S. Endometriosis Treatment Market Pipeline Analysis
• 3.8 U.S. Endometriosis Treatment Market Unmet Need Analysis

Chapter 4 U.S. Endometriosis Treatment Market: Competitive Landscape

• 4.1 Recent Developments And Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
  • 4.2.2 Market Leaders
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
• 4.4 Public Companies
  • 4.4.1 Company Market Position Analysis
  • 4.4.2 Competitive Dashboard Analysis
    • 4.4.2.1 Market Differentiators
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies

Chapter 5 U.S. Endometriosis Treatment Market: Treatment Type Business Analysis

• 5.1 U.S. Endometriosis Treatment Market: Treatment Types Movement Analysis
  • 5.1.1 Pain Medication
    • 5.1.1.1 Pain Medication Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.1.2 Hormone Therapy
    • 5.1.2.1 Hormone Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 U.S. Endometriosis Treatment Market: Route Of Administration Business Analysis

• 6.1 U.S. Endometriosis Treatment Market: Route Of Administration Movement Analysis
  • 6.1.1 Oral
    • 6.1.1.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.1.2 Injectable
    • 6.1.2.1 Injectable Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.1.3 Others
    • 6.1.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 U.S. Endometriosis Treatment Market: Drug Class Business Analysis

• 7.1 U.S. Endometriosis Treatment Market: Drug Class Movement Analysis
  • 7.1.1 Nsaids
    • 7.1.1.1 Nsaids Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.2 Oral Contraceptive
    • 7.1.2.1 Oral Contraceptive Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.3 Gonadotropin Releasing Hormone
    • 7.1.3.1 Gonadotropin Releasing Hormone Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.4 Others
    • 7.1.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 U.S. Endometriosis Treatment Market: Distribution Channel Business Analysis

• 8.1 U.S. Endometriosis Treatment Market: Distribution Channel Movement Analysis
  • 8.1.1 Hospital Pharmacy
    • 8.1.1.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.1.2 Retail Pharmacy
    • 8.1.2.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.1.3 Others
    • 8.1.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 U.S. Endometriosis Treatment Market: Company Profiling

• 9.1 Company Profiles
  • 9.6.1 Bayer Ag
  • 9.6.2 Pfizer, Inc.
  • 9.6.3 Abbvie, Inc.
  • 9.6.4 Astrazeneca
  • 9.6.5 Obseva Sa
  • 9.6.6 Teva Pharmaceutical Industries
  • 9.6.7 Zydus Healthcare Limited
  • 9.6.8 Eli Lilly And Company
  • 9.6.9 Astellas Pharma Inc.

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Endometriosis Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 4. U.S. Endometriosis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 5. U.S. Endometriosis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 6. U.S. Endometriosis Treatment Market, Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. Endometriosis Treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. Endometriosis Treatment Market Outlook (2021)
• Fig. 9 User perspective analysis
• Fig. 10 Penetration & growth prospect mapping
• Fig. 11 Market driver relevance analysis (Current & future impact)
• Fig. 12 Global population by age group, 2018, 2021, & 2030
• Fig. 13 General trend shifts from laboratory to point-of-care
• Fig. 14 Market restrain relevance analysis (Current & future impact)
• Fig. 15 Porter's five forces analysis
• Fig. 16 SWOT analysis, by factor (Political & legal, economic and technological)
• Fig. 17 Strategy mapping
• Fig. 18 U.S. Endometriosis Treatment market: Treatment Types outlook and key takeaways
• Fig. 19 U.S. Endometriosis Treatment market: Treatment Types movement analysis
• Fig. 20 Pain Medication market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Hormone Therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 U.S. Endometriosis Treatment market: Drug Class outlook and key takeaways
• Fig. 23 U.S. Endometriosis Treatment market: Drug Class movement analysis
• Fig. 24 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Oral Contraceptivies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Gonadotropin Releasing Hormone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 U.S. Endometriosis Treatment market: Route of Administration movement analysis
• Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Endometriosis Treatment market: Distribution Channel outlook and key takeaways
• Fig. 33 U.S. Endometriosis Treatment market: Distribution Channel movement analysis
• Fig. 34 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Company market position analysis
• Fig. 38 Company market position analysis
• Fig. 39 Market differentiators